2022
Kidney Cancer, Version 3.2022, NCCN Clinical Practice Guidelines in Oncology.
Motzer RJ, Jonasch E, Agarwal N, Alva A, Baine M, Beckermann K, Carlo MI, Choueiri TK, Costello BA, Derweesh IH, Desai A, Ged Y, George S, Gore JL, Haas N, Hancock SL, Kapur P, Kyriakopoulos C, Lam ET, Lara PN, Lau C, Lewis B, Madoff DC, Manley B, Michaelson MD, Mortazavi A, Nandagopal L, Plimack ER, Ponsky L, Ramalingam S, Shuch B, Smith ZL, Sosman J, Dwyer MA, Gurski LA, Motter A. Kidney Cancer, Version 3.2022, NCCN Clinical Practice Guidelines in Oncology. Journal Of The National Comprehensive Cancer Network 2022, 20: 71-90. PMID: 34991070, PMCID: PMC10191161, DOI: 10.6004/jnccn.2022.0001.Peer-Reviewed Original ResearchConceptsRenal cell carcinomaStage IV renal cell carcinomaNCCN guidelinesKidney cancerTreatment selectionNCCN Clinical Practice GuidelinesAdvanced renal cell carcinomaSystemic therapy recommendationsFirst-line treatmentPre-existing comorbiditiesClinical practice guidelinesKidney cancer therapyRecommended regimensSystemic therapyRisk stratificationTumor histologyCell carcinomaTreatment recommendationsTherapy recommendationsRisk groupsPractice guidelinesCancer fociTherapy selectionCancer panelPatients
2020
NCCN Guidelines Insights: Kidney Cancer, Version 1.2021.
Motzer RJ, Jonasch E, Boyle S, Carlo MI, Manley B, Agarwal N, Alva A, Beckermann K, Choueiri TK, Costello BA, Derweesh IH, Desai A, George S, Gore JL, Haas N, Hancock SL, Kyriakopoulos C, Lam ET, Lau C, Lewis B, Madoff DC, McCreery B, Michaelson MD, Mortazavi A, Nandagopal L, Pierorazio PM, Plimack ER, Ponsky L, Ramalingam S, Shuch B, Smith ZL, Somer B, Sosman J, Dwyer MA, Motter AD. NCCN Guidelines Insights: Kidney Cancer, Version 1.2021. Journal Of The National Comprehensive Cancer Network 2020, 18: 1160-1170. PMID: 32886895, PMCID: PMC10191771, DOI: 10.6004/jnccn.2020.0043.Peer-Reviewed Original ResearchConceptsRenal cell carcinomaKidney cancerStage IV renal cell carcinomaHereditary RCC syndromesNCCN Guidelines InsightsSystemic therapy recommendationsTreatment of patientsNCCN guidelinesRCC syndromesCell carcinomaMultidisciplinary recommendationsTreatment optionsDiagnostic workupTherapy recommendationsGenetic testingPatientsSyndromeCancerRecent updatesGuidelinesCarcinomaWorkupStagingRecommendationsIs There a Role for Combination, Single-Session Selective Transarterial Embolization and Microwave Ablation for Large Renal Masses?
LaRussa S, Vanden Berg RW, Craig KM, Madoff DC, McClure TD. Is There a Role for Combination, Single-Session Selective Transarterial Embolization and Microwave Ablation for Large Renal Masses? CardioVascular And Interventional Radiology 2020, 43: 1468-1473. PMID: 32613266, DOI: 10.1007/s00270-020-02568-5.Peer-Reviewed Original ResearchConceptsLarge renal massTransarterial embolizationRenal tumorsRenal massesMicrowave ablationCharleston Comorbidity IndexLarge renal tumorsEvidence of recurrencePost-procedure complicationsAverage tumor sizeSelective transarterial embolizationSmall renal tumorsClear cell carcinomaMeeting inclusion criteriaPatient demographic informationGroin hematomaComorbidity indexResultsEleven patientsAverage BMICase seriesSuccessful ablationTumor sizeCell carcinomaMean ageRENAL score
2019
Extrahepatic Clinical Application of Vessel Tracking Software and 3D Roadmapping Tools: Preliminary Experience
Sundararajan SH, McClure TD, Winokur RS, Kishore SA, Madoff DC. Extrahepatic Clinical Application of Vessel Tracking Software and 3D Roadmapping Tools: Preliminary Experience. Journal Of Vascular And Interventional Radiology 2019, 30: 1021-1026. PMID: 31003843, DOI: 10.1016/j.jvir.2018.11.039.Peer-Reviewed Original ResearchMeSH KeywordsAgedAneurysm, FalseCarcinoma, Renal CellComputed Tomography AngiographyEmbolization, TherapeuticFemaleGastrointestinal HemorrhageHumansImaging, Three-DimensionalKidney NeoplasmsMaleMesenteric Artery, SuperiorPancreaticoduodenectomyPostoperative HemorrhagePredictive Value of TestsPreliminary DataProstateProstatic HyperplasiaRadiographic Image Interpretation, Computer-AssistedRadiography, InterventionalRenal ArteryRetrospective StudiesSoftwareTreatment Outcome
2005
Hepatic arterial embolization and chemoembolization for the treatment of patients with metastatic neuroendocrine tumors
Gupta S, Johnson MM, Murthy R, Ahrar K, Wallace MJ, Madoff DC, McRae SE, Hicks ME, Rao S, Vauthey J, Ajani JA, Yao JC. Hepatic arterial embolization and chemoembolization for the treatment of patients with metastatic neuroendocrine tumors. Cancer 2005, 104: 1590-1602. PMID: 16134179, DOI: 10.1002/cncr.21389.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAntineoplastic Combined Chemotherapy ProtocolsCarcinoid TumorCarcinoma, Islet CellChemoembolization, TherapeuticDisease-Free SurvivalEmbolization, TherapeuticFemaleFollow-Up StudiesHepatic ArteryHumansLiver NeoplasmsMaleMedical RecordsMiddle AgedPrognosisRetrospective StudiesRisk FactorsSurvival RateConceptsHepatic arterial embolizationProgression-free survivalIslet cell carcinomaMetastatic neuroendocrine tumorsIntact primary tumorOverall survivalCarcinoid tumorsCell carcinomaHigh response rateNeuroendocrine tumorsMultivariate analysisArterial embolizationBone metastasesPrimary tumorMale genderRisk factorsPrognostic variablesResponse rateOnly independent risk factorLonger progression-free survivalPancreatic islet cell carcinomaExtensive liver diseaseOutcomes of patientsIndependent risk factorOnly risk factor